Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 2Phase 3 1

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Uterine Cervical Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Ovarian Neoplasms 5Cholangiocarcinoma 5Squamous Cell Carcinoma of Head and Neck 4Pancreatic Neoplasms 4Small Cell Lung Carcinoma 3Prostatic Neoplasms 3Neuroblastoma 3Lung Neoplasms 3Gallbladder Neoplasms 3Fallopian Tube Neoplasms 3Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Mesothelioma, Malignant 2Klatskin Tumor 2Ganglioneuroblastoma 2Colorectal Neoplasms 2Carcinoma, Transitional Cell 2Breast Neoplasms 2Adenocarcinoma of Lung 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Neoplasms 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Testicular Neoplasms 1Seminoma 1Sarcoma 1Pinealoma 1

Interventions

Paclitaxel 81Trastuzumab 76Fulvestrant 55Cyclophosphamide 49Capecitabine 42Lapatinib 40pembrolizumab 39Docetaxel 38palbociclib 36Carboplatin 33Letrozole 28olaparib 23Doxorubicin 23Gemcitabine 21Taxes 20Everolimus 20ribociclib 19abemaciclib 19Ado-Trastuzumab Emtansine 18pertuzumab 17Radiotherapy 17Magnetic Resonance Spectroscopy 17Bevacizumab 16130-nm albumin-bound paclitaxel 16exemestane 15Vinorelbine 15Cisplatin 15veliparib 14Biopsy 14Alpelisib 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Breast Neoplasms × Platinum × Clear all
NCT06351332 2026-06-04

ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC

Dana-Farber Cancer Institute

Phase 1 Terminated
7 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06769425 2025-06-24

HS-10502

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Phase 1 Recruiting
157 enrolled
BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡